People with cystic fibrosis (CF) can have a complicated relationship with food and eating that changes over their lifetime,…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
First Wave BioPharma has filed two new patents related to adrulipase, a yeast-derived enzyme that the company is developing…
The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of…
The European Commission has expanded its approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat children with cystic…
Researchers at The Rockefeller University in New York City have determined how two medications used to treat cystic fibrosis…
The Cystic Fibrosis Foundation has announced an investment in SalioGen Therapeutics to support the company’s preclinical research toward…
EnBiotix has raised $11 million in financing that will help fund clinical testing of ColiFin (inhaled colistimethate sodium) and…
An endoscopic sinus surgery (ESS) is best performed within a few years of a lung transplant in cystic…
People in the U.K. at highest risk of becoming seriously ill from COVID-19 — including those with cystic fibrosis (CF)…
Blocking the protein SGLT1, which regulates glucose uptake in cells, may be a useful in treating cystic fibrosis (CF), according…